News

SB 11 filed with EMA for retinal vascular disorders.- Samsung Bioepis + Biogen

Read time: 1 mins

Published:7th Oct 2020

Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for SB 11 (ranibizumab biosimilar) referencing Lucentis. Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (U.S.), Canada, Europe, Japan and Australia.

Condition: Age Related Macular Degeneration

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA accepts NDA for SH 201 the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers

The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers

1 mins

Drug news

Sphere 360 pulse field ablation catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation

Medtronic plc, announced positive clinical trial safety and efficacy results for Sphere-360 , an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib)

2 min

Drug news

Late-breaking data presented at AAN supporting long-term safety and efficacy of atogepant (Qulipta) for preventive treatment of migraine - AbbVie

AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.

2 min

See all news